You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. RFA-DA-25-054: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)

    Release Date: 01-29-2024Open Date: 06-25-2024Due Date: 07-25-2024Close Date: 07-26-2024

    Background: Drug discovery and development is a high-cost, high-risk, and time-consuming endeavor where the failure rate of therapeutic candidates that enter clinical trials is 90%. Because of this, in recent years, artificial intelligence (AI), including machine learning ( ML) technologies, has been embraced to reduce clinical failure rates and to speed up drug discovery. AI/ML technologies are ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. RFA-DA-25-053: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)

    Release Date: 01-29-2024Open Date: 06-25-2024Due Date: 07-25-2024Close Date: 07-26-2024

    Background: Drug discovery and development is a high-cost, high-risk, and time-consuming endeavor where the failure rate of therapeutic candidates that enter clinical trials is 90%. Because of this, in recent years, artificial intelligence (AI), including machine learning (ML) technologies, has been embraced to reduce clinical failure rates and to speed up drug discovery. AI/ML technologies are u ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. RFA-MD-24-007: Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)

    Release Date: 03-08-2024Open Date: 05-10-2024 Due Dates: Multiple Close Date: 12-10-2026

    Background Despite continued improvement in the health of the U.S. population with the introduction of medical and scientific advances, there continues to be an alarming disproportionate burden of illness among certain population groups. The mission of the NIMHD is to lead scientific research aimed at the development of innovative diagnostics, treatments, and prevention strategies to improve mino ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-MD-24-006: Innovations for Healthy Living- Improving Minority Health and Eliminating Health Disparities (R43/R44- Clinical Trial Optional)

    Release Date: 03-08-2024Open Date: 05-10-2024 Due Dates: Multiple Close Date: 12-10-2026

    Background Despite continued improvement in the health of the U.S. population with the introduction of medical and scientific advances, there continues to be an alarming disproportionate burden of illness among certain population groups. The mission of the NIMHD is to lead scientific research aimed at the development of innovative diagnostics, treatments, and prevention strategies to improve mino ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAR-24-107: Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Optional)

    Release Date: 01-09-2024Open Date: 04-30-2024Due Date: 05-30-2024Close Date: 05-31-2024

    Purpose This Notice of Funding Opportunity (NOFO) invites applications from eligible small businesses to develop solutions for commercialization that can be used to enable regional clinician-to-clinician genomic medicine eConsult services. Specifically, we seek products, such as technologies or services, that will allow for the development and sustainment of eConsult services. Eligible United Sta ...

    STTRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PAR-24-099: NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)

    Release Date: 01-29-2024Open Date: 04-12-2024 Due Dates: Multiple Close Date: 01-14-2027

    Purpose This Notice of Funding Opportunity (NOFO) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. This program provides support for milestone-driven, hypothesis-driven clinical trials related to the research mi ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. DHA244-D001: Sample Collection and Processing Methods to Support Battlefield Wound Infection Diagnostics (Direct to Phase II)

    Release Date: 10-03-2023Open Date: 03-26-2024Due Date: 03-31-2025Close Date: 05-13-2025

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Military Infectious Disease OBJECTIVE: This topic is intended for technology proven ready to move directly into Phase II and is accepting Direct to Phase II proposals only. Develop a simple-to-use sample collection and processing method capable of preparing an adequate specimen for subsequent identification and accurate detection of specific fungal and/o ...

    SBIRPhase I/Phase IIDepartment of DefenseDefense Health Agency
  8. DHA244-D002: Innovative Solutions for Ethylene Oxide Mitigation Used in Sterilization Processes (Direct to Phase II)

    Release Date: 10-03-2023Open Date: 03-26-2024Due Date: 03-31-2025Close Date: 05-13-2025

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Combat Casualty Care OBJECTIVE: This topic is intended for technology proven ready to move directly into Phase II and is accepting Direct to Phase II proposals only. Develop innovative solutions that effectively mitigate ethylene oxide used as part of and generated during sterilization processes, promoting environmentally friendly and sustainable practic ...

    SBIRPhase I/Phase IIDepartment of DefenseDefense Health Agency
  9. DHA244-D003: Advanced Information Technology to Improve Mobility, Interoperability, and Survivability of Expeditionary Medical Command, Control, Communications, and Computers (Direct to Phase II)

    Release Date: 10-03-2023Open Date: 03-26-2024Due Date: 03-31-2025Close Date: 05-13-2025

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Combat Casualty Care OBJECTIVE: This topic is intended for technology proven ready to move directly into Phase II and is accepting Direct to Phase II proposals only. Develop expeditionary and interoperable information technology (IT) to enable health care delivery (HCD), medical command and control (MEDC2), medical logistics (MEDLOG), and patient movemen ...

    SBIRPhase I/Phase IIDepartment of DefenseDefense Health Agency
  10. SOCOM244-006: Digital Projection Close Quarters Sight (DP-CQS)

    Release Date: 10-03-2023Open Date: 03-25-2024Due Date: 03-31-2025Close Date: 05-13-2025

    OUSD (R&E) CRITICAL TECHNOLOGY AREA(S): Microelectronics; Human-Machine Interfaces. The technology within this topic is restricted under the International Traffic in Arms Regulation (ITAR), which controls the export and import of defense-related material and services. Offerors must disclose any proposed use of foreign nationals, their country of origin, and what tasks each would accomplish in ...

    SBIRPhase I/Phase IIDepartment of DefenseSpecial Operations Command
US Flag An Official Website of the United States Government